ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc., a Shionogi Company, today announced that it has acquired the global rights for PSD502 from Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC (“Plethora” – AIM:PLE). Under the terms of the agreement, Sciele has made payments totaling $8.4 million to Plethora, its debt holders, and the inventor of the product. Sciele will also share development costs for PSD502 for non-US territories and pay Plethora a royalty on non-US revenues.
